Cambridge Healthtech Institute’s 2nd Annual
Immunomodulatory Therapeutic Antibodies for Cancer
Michael A. Postow, M.D., Assistant Attending Physician, Melanoma and Immunotherapeutics Service, Memorial Sloan-Kettering Cancer Center
Michael Postow, MD is an Assistant Attending Physician in the Melanoma and Immunotherapeutics Service at Memorial Sloan-Kettering Cancer Center. He completed internal medicine residency training at Brigham and Women’s Hospital and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center where he conducted research under the mentorship of Dr. Jedd Wolchok. Dr. Postow’s clinical focus is dedicated to the care of patients with advanced melanoma. His research interests include conducting clinical trials of novel immunomodulatory antibodies alone and in combination with other anticancer agents and investigating immunologic biomarkers associated with clinical outcomes. In his spare time, he enjoys sailing in the New York City Harbor and snow skiing.
Weiming Yuan, Ph.D., Assistant Professor - Department of Molecular Microbiology and Immunology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California.
Weiming Yuan joined the Department of Molecular Microbiology and Immunology and the Norris Comprehensive Cancer Center at USC Keck School of Medicine in 2009. He received his Ph.D. in Molecular Biology from the University of Texas at Austin and performed postdoctoral training in Department of Immunobiology at Yale University School of Medicine. Dr. Yuan’s research interest is to understand the role of NKT cells and its regulation by CD1d lipid presentation during immunity against cancer and infections. Specifically he is mostly interested in understanding the in-vivo characteristics of human CD1d/NKT system building upon our knowledge of mouse system with the long-term goal of harnessing the CD1d/NKT system for anti-tumor and anti-infection therapies. Dr. Yuan’s research has been supported by the National Institutes of Health, the pharmaceutical industry and several private foundations for biomedical research.
Paul D. Rennert, Founder & Principal, SugarCone Biotech Consultants LLC
Paul is a top-tier Biotech Executive with strong strategic and leadership experience. His expertise covers bench to IND development of biological and small molecule drugs for oncology, autoimmunity, chronic inflammation and fibrosis. His corporate strategy expertise includes deep experience building biotech portfolios, discovering novel targets, and anticipating competitive, commercial and clinical landscapes. He founded SugarCone Biotech Consultants LLC as a platform for bringing this expertise to diverse clients, with a keen focus on the alignment of research, commercial and clinical strategy to drive successful drug development and to create value for companies and investors.
Ana Carrizosa Anderson, Ph.D., Assistant Professor, Neurology, Harvard Medical School
Dr. Anderson is an Assistant Professor of Neurology at Harvard Medical School and Associate Scientist at the Brigham and Women’s Hospital, Boston. She obtained her B.S. in Microbiology and Immunology in 1993 from the University of Miami, where she graduated summa cum laude. She obtained her Ph.D. in Immunology from Harvard University in 1999. During her Ph.D. she was awarded a fellowship from the Howard Hughes Medical Institute. Dr. Anderson works in the field of cancer immunology, specifically on the role of inhibitory molecules in regulation of the anti-tumor T cell response. Her laboratory identified the inhibitory molecule Tim-3 as a key regulator of T cell dysfunction in cancer. Prior to working in the field of cancer immunology, Dr. Anderson worked in the field of autoimmunity. Dr. Anderson has published over 38 original papers, 12 reviews, and 5 book chapters. Her work on T cell cross-reactivity in auotimmunity was selected by Nature Immunology as a ‘Classic Paper in Autoimmunity’. She has also had several papers selected as either ‘must-read’ or ‘recommended’ by the Faculty of 1000. Dr. Anderson is on the editorial board for OncoImmunology and currently serves on the scientific advisory board for CoStim Pharmaceuticals, Inc.
Robert B. Stein, M.D., Ph.D., Chief Scientific Officer, Agenus
Robert Stein, MD, PhD, Chief Scientific Officer of Agenus, leads Research, Preclinical Development and Translational Medicine functions and helps shape the clinical development strategy for the Prophage Series vaccines and HerpV. In addition, he's leading integration of the 4-Antibody acquisition, which includes the company's fully-human antibody drug discovery and optimization technology platform and portfolio of immune checkpoint antibody programs. Bob brings over 30 years of experience and accomplishments in the pharmaceutical and biotech industry to the Agenus leadership team. Over the course of his career Bob has played a pivotal role in bringing eight drugs to the market including Sustiva®, Fablyn®, Viviant®, PanRetin®, TargRetin®, Promacta®, & Eliquis®. Prior to joining Agenus he held a number of progressively responsible senior management positions including CSO & SVP of Research for Ligand Pharmaceuticals, EVP of Research & Preclinical Development for Dupont Merck, President and CSO for Incyte Pharmaceuticals, President of Roche Palo Alto and CEO of KineMed. Bob spent the early part of his career at Merck, Sharp and Dohme Research Laboratories. He holds an MD and a PhD in Physiology & Pharmacology from Duke University.
Laszlo Radvanyi, Ph.D., Professor, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Dr. Laszlo Radvanyi received his Ph.D. degree in Clinical Biochemistry in 1996 at the University of Toronto, Toronto, Canada. He completed postdoctoral work in Immunology working on T-cell development at Harvard University under the mentorship of Drs. Diane Mathis and Christophe Benoist. Dr. Radvanyi then moved on to become a Senior Research Scientist in the Immunology Platform at Sanofi-Pasteur in Toronto, Canada in 2000 where he worked on antigen discovery and developing tumor vaccines for breast cancer. He then joined the University of Texas, M.D. Anderson Cancer Center in Houston in 2005, where he is currently a Professor in the Department of Melanoma Medical Oncology. He also is cross-appointed to the Department of Breast Medical Oncology. Dr. Radvanyi’s current work focuses on tumor immunotherapy with a specific focus on adoptive T-cell therapy for melanoma, in particular using tumor-infiltrating lymphocytes (TIL). He oversees all clinical-grade manufacturing of T-cell products in these clinical trials and performs basic and translational research identifying biomarkers in T-cell therapy, improving the anti-tumor function of expanded T cells using novel ex vivo cell expansion technologies and combination therapies in vivo, and developing manufacturing methods for eventual out-scaling and commercialization of T-cell therapy.
Taylor Schreiber, M.D., Ph.D., Chairman, Scientific Advisory Board, Pelican Therapeutics
Dr. Schreiber is the co-inventor of the TNFRSF25 agonist technology together with Dr. Eckhard R. Podack. Dr. Schreiber received his Ph.D. degree from the Sheila and David Fuente Program in Cancer Biology at the University of Miami Miller School of Medicine in 2010. Following his degree, Dr. Schreiber completed a post-doctoral fellowship with Dr. Podack studying the immunobiology of TNFRSF25 from 2010-2012. Dr. Schreiber received the best overall research award at the National Student Research Forum in 2008 and was nominated as a Future Leader in Cancer Research by the American Association for Cancer Research in 2011. He later completed his M.D. also at the Miller School of Medicine in 2014. Dr. Schreiber is an emerging expert in the field of tumor immunology and TNFRSF25 biology. Dr. Schreiber received his B.A. in Biology from Bucknell University.
Llew Keltner, MD, PhD, Chief Executive Officer, EPISTAT
Llew Keltner, M.D., Ph.D. has a 30 year career in biopharma drug and business development. He is Chief Executive Officer of EPISTAT, an international healthcare technology transfer, corporate risk management and healthcare strategy company that he founded in 1972. Dr. Keltner was the Chief Executive Officer of AgonOx, a biotech company developing OX40 agonists for use in cancer therapy, from 2011 to 2013. He was the President of Novici Biotech, a privately-held gene and protein optimization firm in 2010 and 2011. Dr. Keltner was Chief Executive Officer and President of Light Sciences Oncology, a privately-held biotechnology company developing a late stage, light-activated therapy for hepatocellular cancer and other solid tumors from 2001 to 2010. From 1997 to 2004, Dr. Keltner was Chief Executive Officer of Metastat, a development-stage biotech company focused on cancer metastasis.
Dr. Keltner holds positions on the boards of Raptor Pharmaceuticals, where he serves as Chairman (NASDAQ:RPTP), Infostat, BioQuiddity, Oregon Life Sciences, and Goodwell Technologies. He is a previous Director of Light Sciences Corporation, Vital Choice, Thesis Technologies, Oread Companies, and MannKind Corporation (NASDAQ:MNKD). He has also been a scientific advisory board member at Lifetime Corporation, ASB Meditest, Oread Laboratories, Hall-Kimbrell, and aai Pharma. Dr. Keltner is an Associate Professor at Case Western Reserve School of Medicine, and a Guest Lecturer and Director in the Bioethics Program at Columbia University School of Medicine. He is currently a member of the American Society of Clinical Oncology, American Medical Association, International Association of Tumor Marker Oncology, American Association of Clinical Chemistry, and Drug Information Association. Dr. Keltner received an M.S. in Epidemiology and Biostatistics, a Ph.D. in Biomedical Informatics and an M.D. from Case Western Reserve University in Cleveland, Ohio. Dr. Keltner has also authored many research publications.
Denise Faustman, M.D., Ph.D., Director, Immunobiology; Associate Professor, Medicine, Immunobiology, Massachusetts General Hospital & Harvard Medical School
Denise Faustman, MD, PhD, is Director of the Immunobiology Laboratory at the Massachusetts General Hospital (MGH) and an Associate Professor of Medicine at Harvard Medical School. Her research accomplishments include the development of a clinical trial program testing the BCG vaccine in advanced type 1 diabetes and the first scientific description of modifying donor tissue antigens to change their foreignness. This former discovery is the basis for her discovered defects in TNF/NFkB signaling in diverse human and murine autoimmune disease. This latter achievement earned her the prestigious National Institutes of Health and National Library of Medicine “Changing the Face of Medicine” Award (2003) as one of 300 American physicians (one of 35 in research) honored for seminal scientific achievements in the United States. Dr. Faustman earned her MD and PhD from Washington University School of Medicine in St. Louis, Missouri, and completed her internship, residency, and fellowships in Internal Medicine and Endocrinology at the Massachusetts General Hospital in Boston, Massachusetts.
Jacqueline Doody, Vice President, Immunology, F-star Biotechnology Ltd
Jacqueline Doody is the Vice President of F-star Biotechnology Ltd. focusing on Immuno-oncology. She comes with a diverse background in both academia and industry and has successfully moved several antibodies into the clinic.